natgillin/translations-raw huggingface dataset:
The only safety concerns for human use derived from animal studies of salmeterol and fluticasone propionate given separately were effects associated with exaggerated pharmacological actions.
Jedini razlog za zabrinutost oko sigurnosti primjene u ljudi proizašao iz ispitivanja zasebno primjenjivanih salmeterola i flutikazonpropionata na životinjama bili su učinci povezani s pretjeranim farmakološkim djelovanjima.
The onset of action of Cosentyx 150 mg occurred as early as Week 1 for ASAS 20 and Week 2 for ASAS 40 (superior to placebo) in AS Study 2.
Nastup djelovanja Cosentyxa 150 mg dogodio se već u 1. tjednu za ASAS 20 i 2. tjednu za ASAS 40 (superiorno u odnosu na placebo) u drugom ispitivanju AS-a.
The onset of action of Cosentyx occurred as early as Week 2.
Do nastupa djelovanja Cosentyxa došlo je već u 2. tjednu.
The onset of action of Duaklir Genuair was comparable to the effect of the fast-acting β2-agonist formoterol 12 micrograms.
Nastup djelovanja Duaklir Genuaira bio je usporediv s učinkom brzodjelujućeg β2-agonista formoterola u dozi od 12 mikrograma.
The onset of efficacy is within 12 hours for fleas (C. felis) and within 48 hours for ticks (I. ricinus).
Početak djelovanja je unutar 12 sati za buhe (C. felis) i 48 sati za krpelji (I. ricinus).
The onset of efficacy is within 8 hours for fleas (C. felis) and 12 hours for ticks (I. ricinus).
Početak djelovanja je unutar 8 sati za buhe (C. felis) i 12 sati za krpelji (I. ricinus).
The onset of efficacy is within 8 hours for fleas (C. felis) and 12 hours for ticks (I. ricinus).
Početak djelovanja je unutar 8 sati za buhe (C. felis) i unutar 12 sati za krpelji (I. ricinus).
The onset of infusion related reactions has generally occurred within the first 2-4 months after initiation of treatment with Replagal although later onset (after 1 year) has been reported as well.
Početak reakcija povezanih s infuzijom obično je opažen u prva 2 - 4 mjeseca nakon početka primjene Replagala, iako je prijavljen i kasnije (nakon 1 godine).
The onset of lactic acidosis can be subtle and the symptoms can be non-specific such as vomiting, bellyache (abdominal pain) with muscle cramps, a general feeling of not being well with severe tiredness, and difficulty in breathing.
Laktacidoza može nastupiti suptilno, a njeni simptomi mogu biti nespecifični kao što su povraćanje, bol u trbuhu (bol u abdomenu) uz grčeve mišića, općeniti osjećaj lošeg stanja uz težak umor i otežano disanje.
The onset of neuromuscular blockade may be prolonged up to approximately 4 minutes, and the duration of neuromuscular blockade may be shortened up to approximately 15 minutes after re- administration of rocuronium 1.2 mg/kg within 30 minutes after sugammadex administration.
Nakon ponovne primjene rokuronija u dozi od 1,2 mg/kg unutar 30 minuta od primjene sugamadeksa, neuromuskularna blokada možda će nastupiti s kašnjenjem do oko 4 minute, a trajanje neuromuskularne blokade može biti skraćeno za najviše oko 15 minuta.
The onset of pulmonary signs, such as cough, fever and dyspnoea in association with radiological signs of pulmonary infiltrates and deterioration in pulmonary function may be preliminary signs of acute respiratory distress syndrome (ARDS).
Pojava plućnih znakova, poput kašlja, vrućice i dispneje, zajedno s radiološkim znakovima plućnih infiltrata i pogoršanjem funkcije pluća, mogu biti prvi znaci akutnog sindroma respiratornog distresa odraslih (ARDS).
The onset of pulmonary signs, such as cough, fever and dyspnoea in association with radiological signs of pulmonary infiltrates and deterioration in pulmonary function may be preliminary signs of Acute Respiratory Distress Syndrome (ARDS).
Pojava znakova zahvaćenosti pluća, kao što su kašalj, vrućica i dispneja, povezanih s radiološkim znakovima plućnih infiltrata i propadanja plućne funkcije mogu biti preliminarni znakovi akutnog respiratornog distres sindroma (ARDS).
The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence ( 4 contractions/hour) for 12 hours.
Nastup relaksacije maternice nakon davanja atosibana je brz, pri čemu dolazi do značajnog smanjivanja kontrakcija maternice unutar 10 minuta i postizanja stabilnog smirivanja ( 4 kontrakcija/sat) tijekom 12 sati.
The onset time is 3 days post-zoledronic acid infusion, and the reaction is also referred to using the terms “flu-like” or “post-dose” symptoms.
Vrijeme nastupa je ≤3 dana nakon infuzije zoledronatne kiseline, a reakcije se još zovu “simptomi nalik gripi” ili ˝simptomi nakon doziranja”.
The onset time is 3 days post-zoledronic acid infusion, and the reaction is also referred to using the terms “flu-like” or “post-dose” symptoms.
Vrijeme nastupa je≤3 dana nakon infuzije zoledronatne kiseline, a reakcije se još zovu “simptomi nalik gripi” ili “simptomi nakon doziranja”.
The OPA GMTs were similar or higher following a single dose than a 3 dose primary course in infants below 6 months of age, except for serotype 5.
OPA GMT-i su bili podjednaki ili viši nakon jedne doze nego nakon primarnog ciklusa cijepljenja dojenčadi mlađe od 6 mjeseci s tri doze, osim za serotip 5.
The open label extension study showed improvement and/or maintenance of these effects up to
U otvorenom produžetku ispitivanja primijećeno je poboljšanje i/ili održavanje tih učinaka do
The open label period of the study provided an assessment of the ability of abatacept to maintain efficacy for subjects originally randomized to abatacept and the efficacy response of those subjects who were switched to abatacept following treatment with infliximab.
Otvorena faza ispitivanja omogućila je procjenu sposobnosti abatacepta da održi djelotvornost u ispitanika koji su početno bili randomizirani na abatacept kao i procjenu djelotvornosti u onih ispitanika koji su prebačeni na abatacept nakon liječenja infliksimabom.
The open, prospective, single-arm clinical trial enrolled 23 liver transplant recipients, who had been receiving intravenous hepatitis B immunoglobulin prophylaxis and subsequently switched to subcutaneous Zutectra.
U otvorenom, prospektivnom, kliničkom ispitivanju s jednom ispitivanom skupinom bilo je uključeno 23 primatelja transplantirane jetre koji su profilaktički dobivali intravenski imunoglobulin protiv hepatitisa B i nakon toga su prebačeni na supkutanu primjenu lijeka Zutectra.
The open-label, multi-center study (PCYC-1102-CA) included 51 patients with relapsed or refractory CLL, who received 420 mg once daily.
Otvoreno, multicentrično ispitivanje (PCYC-1102-CA) uključivalo je 51 bolesnika s relapsnim ili refrakotornim KLL-om, koji su primili 420 mg jedanput dnevno.
The ophthalmologist may prescribe antibiotic eye drops before and after treatment with Jetrea to prevent eye infections.
Oftamolog može propisati antibiotske kapi za oči prije i nakon terapije lijekom Jetrea kako bi se spriječila očna infekcija.
The opposite side is marked with the company symbol.
Suprotna strana označena je simbolom tvrtke.
The Oprymea treatment initiation pack contains three blister strips of tablets - one strip for each of the first three weeks of your treatment.
Oprymea pakiranje za početno liječenje sadrži 3 blister trake tableta – jedna traka za svaki od tri tjedna Vašeg liječenja.
The optimal therapeutic management of patients with YMDD mutant HBV has not yet been established (see section 4.4).
Optimalan terapijski pristup bolesnicima s YMDD tipom virusa još nije utvrđen (vidjeti dio 4.4).
The optimal treatment duration is unknown.
Optimalno trajanje liječenja nije poznato.
The optimum dosage is based upon the degree and chronicity of the anaemia and the desired duration of the effect. (See Table A Pharmacokinetic Parameters)
Optimalna doza temelji se na stupnju i kroničnosti anemije i željenom trajanju utjecaja proizvoda. (Vidjeti tablicu A Farmakokinetički parametri)
The OPTISON vial must be inverted and gently rotated for approximately three minutes to completely resuspend the microspheres.
Bočicu s lijekom OPTISON morate preokrenuti i lagano zakretati približno tri minute kako bi se mikrosfere u potpunosti raspršile u suspenziju.
The oral absorption of enoxaparin is unlikely.
Oralna apsorpcija enoksaparina nije vjerojatna.
The oral administration of spinosad and milbemycin oxime combination tablets at mean cumulative monthly doses up to 255mg spinosad and 4.2 mg milbemycin oxime per kg body weight (up to
Peroralnu primjenu kombinacije spinosada i milbemicin oksima u tabletama u srednjim kumulativnim mjesečnim dozama do 255 mg spinosada i 4,2 mg milbemicin oksima po kg tjelesne težine (do
The oral bioavailability is approximately 40% higher for Envarsus as compared to the same dose of tacrolimus immediate-release formulation (Prograf) in kidney transplant patients.
Oralna bioraspoloživost je približno 40% viša za Envarsus u usporedbi s istom dozom takrolimusa s trenutnim oslobađanjem (Prograf) u bolesnika s transplantiranim bubregom.
The oral bioavailability of Envarsus was decreased when the product was administered after a meal; the extent of absorption was decreased by 55% and the maximum plasma concentration was decreased by 22% when taken directly after a high-fat meal.
Oralna bioraspoloživost Envarsusa smanjila se kada je lijek bio davan nakon obroka, apsorpcija se smanjila za 55%, a maksimalna koncentracija u plazmi smanjila se za 22% kada se uzimao odmah nakon vrlo masnog obroka.
The oral bioavailability of lacosamide tablets is approximately 100%.
Bioraspoloživost lakozamida nakon peroralne primjene je otprilike 100%.
The oral bioavailability of tenofovir from tenofovir disoproxil fumarate in fasted patients was approximately 25%.
Oralna bioraspoloživost tenofovira iz tenofovirdizoproksilfumarata u pacijenata natašte bila je približno 25%.
The oral bioavailability of tenofovir from tenofovir disoproxil fumarate in fasted patients was approximately 25%.
Peroralna bioraspoloživost tenofovira iz tenofovirdizoproksilfumarata u pacijenata natašte bila je približno 25%.
The oral bioavailability of tenofovir from tenofovir disoproxil fumarate tablets in fasted patients was approximately 25%.
Bioraspoloživost tenofovira iz tableta tenofovirdizoproksilfumarata nakon peroralne primjene u pacijenata natašte bila je približno 25%.
The oral contraceptive pill and alli
Pilule za oralnu kontracepciju i alli
The oral contraceptive pill may be less effective if you get severe diarrhoea.
Pilule za oralnu kontracepciju možda će slabije djelovati ako imate jak proljev.
The oral dispenser from the medicine pack.
štrcaljka za usta (nalazi se u pakiranju lijeka).
The oral dosing syringe and mixing cup should be cleaned immediately with warm water and dish soap after use.
Dozirna štrcaljka za usta i čaša za miješanje se moraju odmah odmah nakon upotrebe oprati toplom vodom i sredstvom za pranje suđa.
The oral dosing syringe and mixing cup should be dry prior to use.
Dozirna štrcaljka za usta i čaša za miješanje moraju biti suhe prije uporabe.
The oral follow-up dose may be administered for up to a total of four doses at 24 hour intervals.
Naknadno oralno doziranje može se primijeniti za ukupno četiri doze u razmacima od 24 sata.
The oral follow-up dose may be administered for up to a total of four doses at 24 hour intervals.
Oralna doza koja slijedi kao nastavak liječenja može se primijeniti do ukupno 4 doze u razmacima od 24 sata.
The oral follow-up dose may be administered for up to a total of four doses at 24 hour intervals..
Naknadno oralno doziranje može se primijeniti za ukupno četiri doze u razmacima od 24 sata.
The oral follow-up dose may be administered once daily (at 24 hour intervals) for up to four days.
Nastavak peroralnog liječenja provodi se jednom dnevno (u razmacima od 24 sata), a može trajati do četiri dana.
The oral follow-up dose may be administered once daily (at 24-hour intervals) for up to 4 days.
Oralna doza koja slijedi kao nastavak liječenja, može se primjenjivati jedanput na dan (u razmacima od 24 sata) do četiri dana.
The oral follow-up dose may be administered once daily (at 24-hour intervals) for up to four days.
Peroralna popratna doza mora se primjenjivati jednom dnevno (u 24- satnim intervalima) tijekom četiri dana.
The oral granules are used to make oral suspensions for children aged 4 weeks and older weighing at least 3 kg.
Oralne granule koriste se za pripremu oralnih suspenzija za djecu stariju od 4 tjedna s tjelesnom težinom od najmanje 3 kg.
The oral LD50 in mouse is 1520 mg/kg.
Oralni LD50 u miševa iznosi 1520 mg/kg.
The oral maintenance dose of 200 mg (or 100 mg for patients less than 40 kg) achieves a voriconazole exposure similar to 3 mg/kg IV.
Peroralnom dozom održavanja od 200 mg (ili 100 mg za bolesnike tjelesne težine manje od 40 kg) postiže se podjednaka izloženost vorikonazolu kao kod intravenske primjene doze od 3 mg/kg.
The oral median lethal dose (LD50) of tolvaptan in rats and dogs is >2000 mg/kg.
Medijan oralne smrtonosne doze (LD50) tolvaptana kod štakora i pasa je >2000 mg/kg.
The oral paste is available in the following pack sizes:
Peroralna pasta dostupna je u sljedećim veličinama pakovanja:
The oral powder is mixed into pig feed by the pig owner and is used to treat individual pigs.
Vlasnik svinje miješa prašak s hranom za svinje te se koristi za liječenje pojedinih svinja.
The oral solution contains fructose and sucrose.
Oralna otopina sadrži saharozu.
The oral solution contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (possibly delayed).
Oralna otopina sadrži metilparahidroksibenzoat i propilparahidroksibenzoat, koji mogu izazvati alergijske reakcije (moguće zakašnjele).
The oral solution has been shown to have greater bioavailability than the soft capsule formulation.
Pokazalo se da oralna otopina ima veću bioraspoloživost od mekih kapsula.
The oral solution is clear to slightly opalescent yellowish, aqueous solution.
Oralna otopina je bistra do lagano opalescentno žućkasta vodena otopina.
The oral solution is prepared by dissolving the amount of powder of one vial in 50 ml of drinking water.
Oralna otopina priprema se otapanjem praška sadržanog u jednoj bočici u 50 ml vode za piće.
The oral solution is the recommended option for the most accurate dosing in children based on body surface area.
Radi najtočnijeg doziranja u djece, preporučuje se oralna otopina zasnovana na površini tijela.
The oral solution or orodispersible tablets can be used in patients who have difficulty swallowing tablets.
Oralna otopina ili raspadljive tablete za usta mogu se koristiti kod bolesnika koji imaju poteškoća u gutanju tableta.
The oral suspension can be kept at room temperature (not above 30oC) for up to 3 hours, prior to administration.
Oralna suspenzija se prije primjene može čuvati na sobnoj temperaturi (ne iznad 30°C) do 3 sata.
The oral suspension can be kept at room temperature (not above 30oC) for up to 3 hours, prior to administration.
Prije primjene oralna suspenzija može se čuvati na sobnoj temperaturi (ne iznad 30°C) do 3 sata.
The oral suspension can be kept at room temperature (not above 30°C) for up to 3 hours, prior to administration.
Prije primjene, oralna suspenzija se može čuvati na sobnoj temperaturi (ne iznad 30°C) do 3 sata.
The oral suspension must be shaken vigorously for a minimum of 10 seconds before use.
Oralna suspenzija se prije uporabe mora snažno tresti najmanje 10 sekundi.
The oral suspension should be given by direct oral administration as shown below:
Peroralna suspenzija daje se izravno u usta kako je prikazano ispod:
The oral suspension should be prepared by the pharmacist using commercially available oseltamivir powder for oral suspension.
Oralnu suspenziju treba pripremiti ljekarnik koristeći se oseltamivirom u prašku za oralnu suspenziju koji je dostupan na tržištu.
The oral syringe graduated in mg provided with this medicine
Oralna štrcaljka s oznakama u mg isporučena s ovim lijekom.
The oral syringe should be cleaned immediately with hot water and dish soap after use.
Štrcaljka za usta se mora odmah nakon upotrebe oprati toplom vodom i sredstvom za pranje suđa.
The orally applied 13C-urea is metabolised to carbon dioxide and ammonia or is integrated into the body’s own urea cycle.
Peroralno primijenjena 13C-urea metabolizira se do ugljičnog dioksida i amonijaka, ili se uključi u metabolizam endogene uree organizma.
the orange cap is missing or not securely attached.
nedostaje narančasti zatvarač ili nije dobro pričvršćen.
The orange cap on a Repatha pre-filled pen contains a needle cover (located inside the cap) that is composed of dry natural rubber, which is made from latex.
Narančasti zatvarač na Repatha napunjenoj brizgalici sadrži pokrov igle (nalazi se unutar zatvarača) koji je načinjen od suhe, prirodne gume koja je napravljena od lateksa.
The orange-banana flavoured chewable tablet is round and pale yellow, marked with the Merck logo on one side and 473 on the other side.
Tableta za žvakanje okusa banane i naranče je okrugla i blijedožuta, s logotipom tvrtke Merck na jednoj i oznakom "473" na drugoj strani.
The order in which other treatments should be taken or carried out
Redoslijed kojim se moraju uzimati ili izvoditi drugi oblici liječenja
The orodispersible tablet is moisture sensitive so should be taken immediately after opening the blister.
Raspadljiva tableta za usta osjetljiva je na vlagu pa je treba uzeti odmah čim se otvori blister.
The orodispersible tablets should not be handled with wet hands as the tablets may break up.
Raspadljivim tabletama za usta ne smije se rukovati mokrim rukama jer se tablete mogu raspasti.
The ORR and DOR were assessed using criteria adopted from the Third International Workshop of Waldenström’s macroglobulinaemia.
ORR i DOR (engl. duration of response, trajanje odgovora) bili su procijenjeni uz korištenje kriterija usvojenih na trećoj internacionalnoj radionici o Waldenströmovoj makroglobulinemiji (engl. the Third International Workshop of Waldenström’s macroglobulinaemia).
The ORR in the Cyramza plus paclitaxel arm was 27.9% and in the placebo plus paclitaxel arm was 16.1%.
Stopa objektivnog odgovora (engl. objective response rate, ORR) iznosila je 27,9% u skupini liječenoj lijekom Cyramza plus paklitakselom te 16,1% u skupini koja je primala placebo plus paklitaksel.
The ORR was 27.9% and 0% for subjects in the cabozantinib arm and placebo arm, respectively (p<0.0001; Table 2).
ORR je iznosio 27,9% za skupinu ispitanika u kojih je primjenjivan kabozantinib i 0% za skupinu ispitanika u kojih je primjenjivan placebo (p<0,0001; Tablica 2).
The ORR was 36 % (CI95 % 21 % – 51 %; CR 3 %, PR 33 %) with a median TTP for responding patients of 9.6 months (range 4.5 to 26.8 months).
21%-51%; CR 3%, PR 33%), a medijan TTP-a u bolesnika koji su odgovorili na liječenje 9,6 mjeseci (raspon od 4,5 do 26,8 mjeseci).
The ORR was 57 % (95% Confidence interval (CI); 41% – 73%; CR 14 %, PR 43%) with a projected median TTP for responding patients of 19.4 months (range 5.3 to 38.9 months).
ORR je iznosio 57% (95% CI 41%-73%; CR 14%, PR 43%), a procijenjeni medijan TTP-a u bolesnika koji su odgovorili na liječenje bio je 19,4 mjeseci (raspon od 5,3 do 38,9 mjeseci).
The ORR was 57% (95% Confidence interval (CI); 41% – 73%; CR 14%, PR 43%) with a projected median TTP for responding patients of 19.4 months (range 5.3 to 38.9 months).
ORR je iznosio 57% (95% CI 41%-73%; CR 14%, PR 43%), a procijenjeni medijan TTP-a u bolesnika koji su odgovorili na liječenje bio je 19,4 mjeseci (raspon od 5,3 do 38,9 mjeseci).
The ORR, DOR and PFS (by BIRC assessment) for patients with brain metastases at baseline were in line with those reported for the overall population of these studies.
ORR, DOR i PFS (prema procjeni BIRC-a) za bolesnike s metastazama na mozgu na početku bili su u skladu s onima zabilježenima za cjelokupnu populaciju ovih ispitivanja.
The OS and PFS benefit was observed consistently, in all relevant pre-specified subgroups, including race, geographic region, age (< 65; ≥ 65), sex, ECOG PS, KRAS status, time since diagnosis of first metastasis, number of metastatic sites, and primary tumour site.
Korist u smislu OS i PFS je konzistentno zabilježena u svih relevantnih, prethodno specificiranih, podskupina, uključujući rasu, geografsku regiju, starost (< 65; ≥ 65), spol, ECOG PS, KRAS status, vrijeme od dijagnoze prve metastaze, broj metastatskih sjela i mjesto primarnog tumora.
The OS data were not mature at the time of the PFS analysis.
Podaci za OS nisu bili zreli u trenutku analize PFS-a.
The OS HRs for pembrolizumab 2 mg/kg every 3 weeks vs. chemotherapy were 0.93 (95% CI: 0.58, 1.49) for PD-L1 positive patients and 1.19 (95% CI: 0.58, 2.46) for PD-L1 negative patients.
HR za OS za pembrolizumab 2 mg/kg svaka 3 tjedna naspram kemoterapije iznosio je 0,93 (95% CI: 0,58; 1,49) za PD-L1 pozitive bolesnike i 1,19 (95% CI: 0,58; 2,46) za PD-L1 negativne bolesnike.
The OS HRs for pooled pembrolizumab vs. chemotherapy were 0.82 (95% CI: 0.55, 1.23) for PD-L1 positive patients and 0.77 (95% CI: 0.43, 1.37) for PD-L1 negative patients.
HR za OS za objedinjene podatke za pembrolizumab naspram kemoterapije iznosio je 0,82 (95% CI: 0,55; 1,23) za PD-L1 pozitivne bolesnike te 0,77 (95% CI:0,43; 1,37) za PD-L1 negativne bolesnike.
The OS HRs for pooled pembrolizumab vs. chemotherapy were 0.83 (95% CI: 0.60, 1.15) for BRAF wild type and 0.82 (95% CI: 0.47, 1.43) for BRAF mutant with prior BRAF treatment.
HR za OS za objedinjene podatke za pembrolizumab naspram kemoterapije iznosio je 0,83 (95% CI: 0,60; 1,15) za bolesnike s divljim tipom gena BRAF te 0,82 (95% CI: 0,47; 1,43) za bolesnike s mutacijom u genu BRAF koji su prethodno primali BRAF terapiju.
The OS rate by specific timepoint is displayed graphically in Figure 4.
Stopa OS u specifičnim vremenskim točkama grafički je prikazana na Slici 4.
The OS results are subject to potential bias as 54 % of patients in the placebo arm also received pazopanib in the extension part of this study following disease progression.
Postoji potencijalna pristranost za OS rezultate jer je 54% bolesnika iz placebo skupine također primalo pazopanib u produžetku ove studije kojom se pratila progresija bolesti.
The osmolality of the medicinal product is controlled between the following range: 270-320 mOsmol/kg
Osmolalnost ovog lijeka kontrolirana je u sljedećem rasponu: 270-320 mOsmol/kg.
The Osmolality of the reconstituted solution is 230-270 mOsmol/kg
Osmolalnost rekonstituirane otopine je 230-270 mOsmol/kg
The osmolality of the reconstituted solution is 230-270 mOsmol/kg.
Osmolalnost rekonstituirane otopine je 230-270 mOsmol/kg
The Otezla 10 mg film-coated tablet is a pink, diamond shaped film-coated tablet with “APR” engraved on one side and “10” on the opposite side.
Otezla 10 mg filmom obložena tableta ružičasta je filmom obložena tableta u obliku romba, s oznakom “APR” utisnutom na jednoj strani i “10” na drugoj strani.
The Otezla 20 mg film-coated tablet is a brown, diamond shaped film-coated tablet with “APR” engraved on one side and “20” on the opposite side.
Otezla 20 mg filmom obložena tableta smeđa je filmom obložena tableta u obliku romba, s oznakom “APR” utisnutom na jednoj strani i “20” na drugoj strani.
The Otezla 30 mg film-coated tablet is a beige, diamond shaped film-coated tablet with “APR” engraved on one side and “30” on the opposite side.
Otezla 30 mg filmom obložena tableta bež je filmom obložena tableta u obliku romba, s oznakom “APR” utisnutom na jednoj strani i “30” na drugoj strani.
The other 2 cases, (dechallenge unknown) were confounded by comorbidity of glaucoma.
U druga 2 slučaja, (dechallenge nepoznat) postojao je zbunjujući čimbenik u vidu istovremeno prisutnog glaukoma.
The other active substance, raltegravir, is an ‘integrase inhibitor’.
Druga djelatna tvar, reltegravir, je "inhibitor integraze".
The other excipients are hypromellose, lactose monohydrate, macrogol 6000, poloxamer 188, magnesium stearate, tartaric acid (E334), butylated hydroxytoluene (E321), dimethicone 350.
Drugi sastojci su hipromeloza, laktoza hidrat, makrogol 6000, poloksamer 188, magnezijev stearat, tartaratna kiselina, butilhidroksitoluen (E321), dimetikon 350.
The other excipients are pregelatinized starch and magnesium stearate.
Pomoćne tvari su prethodno geliran škrob i magnezijev stearat.